Chronic cough is not just annoying. In diseases like Idiopathic Pulmonary Fibrosis (IPF), it’s relentless, debilitating, and poorly managed.
Now, Addex Therapeutics is taking a different approach—one that could shift how chronic cough is treated.
IPF patients don’t just cough more. They cough differently.
Current options are blunt tools. They suppress symptoms, but often bring side effects that limit long-term use. That’s the gap Addex is trying to fill.
Instead of traditional cough suppressants, Addex is focusing on the GABAB receptor pathway. Here’s the logic:
This isn’t theoretical. The drug Baclofen already validates the mechanism. But it comes with problems:
So Addex is doing something smarter.
Instead of directly activating the receptor (like baclofen), Addex is using a positive allosteric modulator (PAM). That means:
Think of it as tuning the signal, not blasting it.
In a bleomycin-induced IPF cough model, the results are promising.
Even more important, safety held up:
This matters. Chronic cough treatments must work long-term, not just acutely.
Addex isn’t a one-asset story.
Their pipeline reflects a broader bet on allosteric modulation in neurological disorders:
This isn’t random. It’s a platform strategy built around precision receptor modulation.
Let’s be clear: this is preclinical data. No human efficacy data yet for chronic cough. But:
If this translates to humans, it could offer:
That’s a big “if”—but a credible one.
Chronic cough in IPF has been stuck with suboptimal treatments for years. Addex’s GABAB PAM approach offers a more refined way forward:
Now it comes down to clinical execution. Because in pharma, promising biology is just the entry ticket.